ZYUS Life Sciences Corporation has successfully closed the second and final tranche of its non-brokered private placement offering, securing an additional $574,999.92 through the issuance of 871,212 units. This completion brings the total capital raised to approximately $1.37 million, bolstering the company's efforts in cannabinoid-based pharmaceutical development for pain management.
The Canadian-based life sciences company, listed on the TSX Venture Exchange (TSX-V: ZYUS), issued a total of 2,083,333 units priced at $0.66 per unit across both tranches of the offering. The first tranche, which closed on May 6, 2025, raised approximately $800,000 through the issuance of 1,212,121 units.
Offering Structure and Terms
Each unit in the offering consists of one common share of ZYUS and one-half of one common share purchase warrant. Each whole warrant entitles the holder to acquire an additional common share at a price of $0.94 for a period of twenty-four months from the issuance date, subject to potential acceleration terms.
The securities issued under the first tranche are subject to a hold period expiring September 7, 2025, while those issued under the second tranche have a hold period until September 16, 2025, in accordance with applicable securities laws and TSX Venture Exchange policies.
The offering has received conditional approval from the TSX Venture Exchange and remains subject to final acceptance. No finder's fees were paid in connection with the offering.
Strategic Focus on Pain Management
ZYUS Life Sciences is focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates specifically targeting pain management solutions. The company aims to address significant unmet needs in the pain treatment landscape through its research and development initiatives.
The global pain management market represents a substantial opportunity, with chronic pain affecting hundreds of millions of patients worldwide and existing treatments often limited by efficacy concerns, side effects, and addiction potential.
Funding Allocation
According to company statements, proceeds from the offering will be directed toward general corporate and working capital purposes. This funding comes at a critical time for pharmaceutical research companies developing novel therapeutic approaches in the cannabinoid space.
The investment reflects continued interest in cannabinoid-based pharmaceuticals as potential alternatives to traditional pain management approaches, particularly as healthcare systems worldwide seek solutions to address the ongoing challenges of pain treatment while minimizing opioid dependence.
Regulatory Compliance
The units were offered through private placement pursuant to exemptions from prospectus requirements under applicable securities laws. The company has emphasized that the securities have not been registered under the United States Securities Act and are not available for offer or sale within the United States except under specific exemptions.
This funding round positions ZYUS to continue advancing its pharmaceutical pipeline while maintaining operational capabilities in an increasingly competitive life sciences landscape.
